Gastrointestinal Stromal Tumors of Small Intestine
Gastrointestinal stromal tumor (GIST) is defined as mesenchymal tumors of the gastrointestinal tract expressing proto-oncogene protein CD117. They are the most common sarcomatous tumors of the gastrointestinal tract. GISTs are presumed to arise from interstitial cells of Cajal or gastrointestinal pa...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical Publishers, Inc.
2019-07-01
|
| Series: | The Surgery Journal |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-1694704 |
| id |
doaj-e2817019cc6a4a1eb7381e00278919ff |
|---|---|
| record_format |
Article |
| spelling |
doaj-e2817019cc6a4a1eb7381e00278919ff2021-04-02T11:23:49ZengThieme Medical Publishers, Inc.The Surgery Journal2378-51282378-51362019-07-010503e92e9510.1055/s-0039-1694704Gastrointestinal Stromal Tumors of Small IntestineTanweerul Huda0Mahendra Pratap Singh1Department of General Surgery, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, IndiaDepartment of General Surgery, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, IndiaGastrointestinal stromal tumor (GIST) is defined as mesenchymal tumors of the gastrointestinal tract expressing proto-oncogene protein CD117. They are the most common sarcomatous tumors of the gastrointestinal tract. GISTs are presumed to arise from interstitial cells of Cajal or gastrointestinal pacemaker cells which control gut motility. They have unpredictable biological behavior. Prognosis is dependent on tumor size as well as mitotic count. Radical surgical excision is the treatment of choice. They rarely metastasize to lymph nodes. Imatinib therapy is used as an adjuvant therapy. The follow-up of patients postsurgery is not standardized.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-1694704gastrointestinal tumorgastrointestinal stromal tumorsjejunal tumorcd117cd34pdgfraimatinib |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Tanweerul Huda Mahendra Pratap Singh |
| spellingShingle |
Tanweerul Huda Mahendra Pratap Singh Gastrointestinal Stromal Tumors of Small Intestine The Surgery Journal gastrointestinal tumor gastrointestinal stromal tumors jejunal tumor cd117 cd34 pdgfra imatinib |
| author_facet |
Tanweerul Huda Mahendra Pratap Singh |
| author_sort |
Tanweerul Huda |
| title |
Gastrointestinal Stromal Tumors of Small Intestine |
| title_short |
Gastrointestinal Stromal Tumors of Small Intestine |
| title_full |
Gastrointestinal Stromal Tumors of Small Intestine |
| title_fullStr |
Gastrointestinal Stromal Tumors of Small Intestine |
| title_full_unstemmed |
Gastrointestinal Stromal Tumors of Small Intestine |
| title_sort |
gastrointestinal stromal tumors of small intestine |
| publisher |
Thieme Medical Publishers, Inc. |
| series |
The Surgery Journal |
| issn |
2378-5128 2378-5136 |
| publishDate |
2019-07-01 |
| description |
Gastrointestinal stromal tumor (GIST) is defined as mesenchymal tumors of the gastrointestinal tract expressing proto-oncogene protein CD117. They are the most common sarcomatous tumors of the gastrointestinal tract. GISTs are presumed to arise from interstitial cells of Cajal or gastrointestinal pacemaker cells which control gut motility. They have unpredictable biological behavior. Prognosis is dependent on tumor size as well as mitotic count. Radical surgical excision is the treatment of choice. They rarely metastasize to lymph nodes. Imatinib therapy is used as an adjuvant therapy. The follow-up of patients postsurgery is not standardized. |
| topic |
gastrointestinal tumor gastrointestinal stromal tumors jejunal tumor cd117 cd34 pdgfra imatinib |
| url |
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-1694704 |
| work_keys_str_mv |
AT tanweerulhuda gastrointestinalstromaltumorsofsmallintestine AT mahendrapratapsingh gastrointestinalstromaltumorsofsmallintestine |
| _version_ |
1724164966229999616 |